VCIM
IOVA icon

Velan Capital Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Velan Capital Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-240,000
Closed -$1.57M – 33
2023
Q2 		$1.69M Buy
240,000
+20,000
+9% +$143K 1.57% 20
2023
Q1 		$1.34M Buy
+220,000
New +$1.52M 1.15% 18

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Velan Capital Investment Management's IOVA Position: Q3 2023 in Review

Velan Capital Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2023, closing a stake of 240,000 shares — an estimated $1.57M sold.

Velan Capital Investment Management first reported a position in IOVA in Q1 2023 and held it in 2 quarters. The position peaked at $1.69M in Q2 2023. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.

  • Velan Capital Investment Management reported no remaining Iovance Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Velan Capital Investment Management sold 240,000 Iovance Biotherapeutics shares in Q3 2023, an estimated $1.57M.
  • Velan Capital Investment Management first reported a position in Iovance Biotherapeutics in Q1 2023 and held it in 2 quarters.
  • Velan Capital Investment Management's Iovance Biotherapeutics position peaked at $1.69M in Q2 2023.
  • 227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.

Based on Velan Capital Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.